LFG316

Phase 2Small molecule

Novartis

LFG316 is one of 171 small molecule programs targeting Panuveitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

170

Competitors

Pipeline

Status by Indication[3][1]

Indication

PanuveitisActive, not recruiting

Macular DegenerationActive, not recruiting

Kidney TransplantActive, not recruiting

Paroxysmal Nocturnal HemoglobinuriaActive, not recruiting

Wet Age-Related Macular DegenerationActive, not recruiting

Geographic AtrophyActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

PanuveitisPhase 2

Active, not recruiting

Macular DegenerationPhase 2

Active, not recruiting

Kidney TransplantPhase 1

Active, not recruiting

Paroxysmal Nocturnal HemoglobinuriaPhase 2

Active, not recruiting

Geographic AtrophyPhase 2

Active, not recruiting

Age-Related Macular DegenerationPhase 1

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

LFG316

Novartis

Phase 2

1 2

Nulojix

Bristol-Myers Squibb

Preclinical

16 3

Medrol

Pfizer

Preclinical

12 4

Zinbryta

Roche

Preclinical

6 5

Zemplar

AbbVie

Preclinical

2 6

Radicava

Shionogi

Preclinical

1 7

Cysteine Hydrochloride

Novartis

Preclinical

1 8

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 10

Jardiance

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration2 trials

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Completed· Novartis logo

Novartis·Phase 2·NCT01527500·158 enrolled

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

Completed· Novartis logo

Novartis·Phase 1·NCT01255462·24 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients

Terminated· Novartis logo

Novartis·Phase 2·NCT02763644·7 enrolled

Panuveitis1 trial

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

Completed· Novartis logo

Novartis·Phase 2·NCT01526889·25 enrolled

Paroxysmal Nocturnal Hemoglobinuria1 trial

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed· Novartis logo

Novartis·Phase 2·NCT02534909·10 enrolled

Kidney Transplant1 trial

Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316

Completed· Novartis logo

Novartis·Phase 1·NCT02878616·8 enrolled

3 more indications

Wet Age-Related Macular Degeneration1 trial

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Terminated· Novartis logo

Novartis·Phase 2·NCT01624636·1 enrolled

Geographic Atrophy1 trial

CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)

Completed·AAlcon Research·Phase 2·NCT02515942·114 enrolled

Macular Degeneration1 trial

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Completed· Novartis logo

Novartis·Phase 2·NCT01535950·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for LFG316. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LFG316 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LFG316. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

LFG316

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Age-Related Macular Degeneration2 trials

Efficacy and Safety1 trial

Panuveitis1 trial

Paroxysmal Nocturnal Hemoglobinuria1 trial

Kidney Transplant1 trial

Wet Age-Related Macular Degeneration1 trial

Geographic Atrophy1 trial

Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News